Avapritinib
GIST
Blueprint Medicines CorporationSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the GIST cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MIDAZOLAM Blueprint Medicines Corporation | Phase 4 | BBB |
Regorafenib Institut Bergonié | Phase 4 | BBB |
Esomeprazole Erasmus Medical Center | Phase 4 | BB |
CAFFEINE Markus Joerger | Phase 4 | BB |
Imatinib M.D. Anderson Cancer Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →